U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C8H11NO4S2
Molecular Weight 249.307
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ERDOSTEINE

SMILES

OC(=O)CSCC(=O)NC1CCSC1=O

InChI

InChIKey=QGFORSXNKQLDNO-UHFFFAOYSA-N
InChI=1S/C8H11NO4S2/c10-6(3-14-4-7(11)12)9-5-1-2-15-8(5)13/h5H,1-4H2,(H,9,10)(H,11,12)

HIDE SMILES / InChI

Molecular Formula C8H11NO4S2
Molecular Weight 249.307
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/18046899, https://www.old.health.gov.il/units/pharmacy/trufot/alonim/ERDOTIN_dr_1322978767512.pdf

Erdosteine is an antioxidant compound developed by Edmond Pharma and approved in Europe for the treatment of chronic bronchitis and COPD. Erdosteine has two thiol groups and is believed to act as a free radicals scavenger (through the formation of the active metabolite I, N-thiodiglycolylhomocysteine). Also the drug effect may be due to the inhibition of the activity of elastase enzyme and its interaction with mucosa. The drug got Orphan Drug designation by FDA for the treatment of bronchiectasis.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ERDOTIN

Approved Use

Mucolytic agent in acute and chronic respiratory diseases.
Primary
ERDOTIN

Approved Use

Mucolytic agent in acute and chronic respiratory diseases.
PubMed

PubMed

TitleDatePubMed
Bacterial adhesiveness: effects of the SH metabolite of erdosteine (mucoactive drug) plus clarithromycin versus clarithromycin alone.
2001 May-Jun
The SH-metabolite I of erdosteine, a mucolytic drug, enhances the inhibitory effect of salbutamol on the respiratory burst of neutrophils.
2002
The combination of the SH metabolite of erdosteine (a mucoactive drug) and ciprofloxacin increases the inhibition of bacterial adhesiveness achieved by ciprofloxacin alone.
2002
Effects on the reactive oxygen species of erdosteine and its metabolite in vitro.
2002
The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study.
2004
Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease [ISRCTN21676344].
2004 Dec 6
Inhibitory effects of metabolite I of erdosteine on the generation of nitric oxide and peroxynitrite chemiluminescence by human neutrophils.
2004 Jul
Erdosteine prevents bleomycin-induced pulmonary fibrosis in rats.
2004 Jun 28
Peroxynitrite decomposition catalyst ameliorates renal damage and protein nitration in cisplatin-induced nephrotoxicity in rats.
2004 Sep 30
Erdosteine ameliorates PTZ-induced oxidative stress in mice seizure model.
2005 May 30
Effect of metabolite I of erdosteine on the release of human neutrophil elastase.
2006
The effects of erdosteine, N-acetylcysteine, and vitamin E on nicotine-induced apoptosis of pulmonary cells.
2006 Feb 15
Erdosteine against acetaminophen induced renal toxicity.
2006 Jul
Comparison of the effects of erdosteine and N-acetylcysteine on apoptosis regulation in endotoxin-induced acute lung injury.
2006 Jul-Aug
Future therapeutic treatment of COPD: struggle between oxidants and cytokines.
2007
Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease.
2007 Dec
Clinical effects of erdosteine in the treatment of acute respiratory tract diseases in children.
2007 Jan
Erdosteine treatment attenuates oxidative stress and fibrosis in experimental biliary obstruction.
2007 Mar
The effects of erdosteine, N-acetylcysteine and vitamin E on nicotine-induced apoptosis of cardiac cells.
2007 May-Jun
Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: a 15-day, prospective, parallel, open-label, pilot study.
2007 Sep
The protective effect of erdosteine against cyclosporine A-induced cardiotoxicity in rats.
2007 Sep 24
The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease.
2008
Antioxidant effect of sulphurous thermal water on human neutrophil bursts: chemiluminescence evaluation.
2008
The effects of erdosteine, N-acetylcysteine, and vitamin E on nicotine-induced apoptosis of hippocampal neural cells.
2008 Aug 1
Antioxidant therapeutic advances in COPD.
2008 Dec
Environmental toxicity, redox signaling and lung inflammation: the role of glutathione.
2009 Feb-Apr
Ambroxol - Resurgence of an old molecule as an anti-inflammatory agent in chronic obstructive airway diseases.
2010 Apr
Beneficial effect of erdosteine on methotrexate-induced testicular toxicity in mice.
2010 Aug
Effects of sulphurous water on human neutrophil elastase release.
2010 Dec
Association between lung function and exacerbation frequency in patients with COPD.
2010 Dec 9
Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention.
2010 Jan 6
Exaggerated liver injury induced by renal ischemia reperfusion in diabetes: effect of exenatide.
2010 Jul-Sep
Patents

Sample Use Guides

1 capsule (300 mg) 2-3 times a day
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 16 19:22:17 UTC 2022
Edited
by admin
on Fri Dec 16 19:22:17 UTC 2022
Record UNII
76J0853EKA
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ERDOSTEINE
INN   MART.   MI   WHO-DD  
INN  
Official Name English
Erdosteine [WHO-DD]
Common Name English
ERDOSTEINE [MART.]
Common Name English
erdosteine [INN]
Common Name English
ERDOSTEINE [MI]
Common Name English
(±)-((((TETRAHYDRO-2-OXO-3-THIENYL)CARBAMOYL)METHYL)THIO)ACETIC ACID
Systematic Name English
MUCOTEC
Brand Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 417413
Created by admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
WHO-ATC R05CB15
Created by admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
WHO-VATC QR05CB15
Created by admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
NCI_THESAURUS C74536
Created by admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
EU-Orphan Drug EU/3/12/1084
Created by admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
Code System Code Type Description
NCI_THESAURUS
C61750
Created by admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
PRIMARY
MESH
C048498
Created by admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
PRIMARY
EVMPD
SUB06595MIG
Created by admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
PRIMARY
ChEMBL
CHEMBL1697744
Created by admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
PRIMARY
RXCUI
24305
Created by admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
PRIMARY RxNorm
DAILYMED
76J0853EKA
Created by admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
PRIMARY
DRUG CENTRAL
1041
Created by admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
PRIMARY
EPA CompTox
DTXSID8048735
Created by admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
PRIMARY
PUBCHEM
65632
Created by admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
PRIMARY
MERCK INDEX
M4974
Created by admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
PRIMARY Merck Index
CAS
84611-23-4
Created by admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
PRIMARY
WIKIPEDIA
ERDOSTEINE
Created by admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
PRIMARY
DRUG BANK
DB05057
Created by admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
PRIMARY
FDA UNII
76J0853EKA
Created by admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
PRIMARY
INN
6032
Created by admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
PRIMARY
Related Record Type Details
ACTIVE MOIETY